Khanna Saira, Komati Rahul, Eichenbaum David A, Hariprasad Ishani, Ciulla Thomas A, Hariprasad Seenu M
Ophthalmology and Visual Sciences, University of Chicago, Chicago, Illinois, USA.
Retina Vitreous Associates of Florida, St. Petersburg, Florida, USA.
BMJ Open Ophthalmol. 2019 Dec 15;4(1):e000398. doi: 10.1136/bmjophth-2019-000398. eCollection 2019.
Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents.
年龄相关性黄斑变性是发达国家视力丧失的主要原因，预计受影响的老年人数量将达到1780万。抗血管内皮生长因子（抗VEGF）注射疗法在治疗一种以前被认为无法治疗的疾病过程中发挥了重要作用。在过去的二十年中，具有里程碑意义的研究已经证明了不同抗VEGF药物的疗效，并研究了最佳给药方案和给药机制，以提高整体视力并减轻患者负担。在这篇综述中，我们概述了具有里程碑意义的新生血管性年龄相关性黄斑变性临床试验，这些试验已经证明了其使用的1级证据，或者有助于理解如何给这些药物给药。
